Brain tumour clinical trial title

SIOP CNS GCT II Prospective trial for the diagnosis of children, adolescents and young adults with intracranial germ cell tumours

Brain tumour type




Malignant intracranial germ cell tumours (GCTs) are either germinoma or nongerminomatous GCTs (NGGCT). Germinoma can be cured by craniospinal irradiation (CSI) alone or by combined treatment with chemotherapy followed by reduced-field radiotherapy, thereby lessening the overall radiotherapy burden. 

The aim for germinoma is to maintain EFS using a risk-adapted approach with standard chemotherapy (carboplatin/ifosfamide/etoposide) for localised disease followed by ventricular radiotherapy. Cases with residual disease after chemotherapy, determined by central radiological review, receive additional tumour boost (16Gy). 

Aims for NGGCT are to improve survival by standardising the surgical approach for residual disease after chemotherapy and intensifying treatment in high-risk patients using high-dose PEI with stem cell support. For all GCTs, data will be collected regarding Quality of Survival to inform future management.

Date added:

Open/Closed: Open

Trial ends: October 2018


Dr John Nicholson, Consultant Paediatric Oncologist

Contact details

Dr James Nicholson :
Cambridge University Hospitals NHS Foundation Trust
Box 181 Addenbrookes Hospital
Telephone: 01223 256298

Find on Google maps »